


Amendments to the Claims:

Listing of Claims:

1. (Original) A compound of formula I:




and salts and solvates thereof, wherein:

R¹⁰ is a nitrogen protecting group and R¹¹ is either OH or O-R¹², wherein R¹² is an oxygen protecting group, or R¹⁰ and R¹¹ together form a double bond between N10 and C11; and R^{10'} and R^{11'} are selected from the same options as R¹⁰ and R¹¹ respectively.

2. (Original) A compound according to claim 1, wherein R^{10'} and R^{11'} are the same as R¹⁰ and R¹¹ respectively.

3. (Currently Amended) A compound according to ~~either claim 1 or claim 2~~, wherein the compounds have the following stereochemistry at the C11 position:



when R¹⁰ and R¹¹ do not form a double bond.

4. (Currently Amended) A compound according to ~~any one of claims 1 to 3~~, wherein the nitrogen protecting groups are selected from carbamate nitrogen protecting groups.
5. (Original) A compound according to claim 4, wherein the nitrogen protecting groups are selected from the group consisting of Alloc, Troc, Teoc, BOC, Doc, Hoc, TcBOC, Fmoc, 1-Adoc and 2-Adoc.

6. (Currently Amended) A compound according to claim 1 ~~or claim 2~~, wherein R¹⁰ and R¹¹ together form a double bond between N10 and C11.
7. (Currently Amended) A compound according to ~~any one of claims 1 to 6~~, wherein at least 50% is in either the E-, E- or Z-, Z- forms.
8. (Currently Amended) A method of synthesising a compound of ~~any one of claims 1 to 7~~.
9. (Currently Amended) A compound of ~~any one of claims 1 to 7~~ and pharmaceutically acceptable salts and solvates thereof, for use in a method of therapy.
10. (Currently Amended) A pharmaceutical composition comprising a compound of ~~any one of claims 1 to 7~~ and pharmaceutically acceptable salts and solvates thereof, and a pharmaceutically acceptable excipient.
11. (Canceled)
12. (Currently Amended) A method for the treatment of a gene-based disease, comprising administering to a subject suffering from a gene-based disease a therapeutically-effective amount of a compound of ~~any one of claims 1 to 7~~ or pharmaceutically acceptable salts and solvates thereof.
13. (Currently Amended) The ~~use of claim 11 or the~~ method of claim 12, wherein the gene-based disease is a proliferative disease.
14. (Currently Amended) The ~~use of claim 11 or the~~ method of claim 12, wherein the gene-based disease is infection by gram-positive bacteria.
15. (Currently Amended) The ~~use or~~ method of claim 14, wherein the gram-positive bacteria is selected from MRSA and VRE.